Alliance Global analyst Scott Henry raised the firm's price target on Fortress Biotech to $4.50 from $4 and keeps a Buy rating on the shares following the Q3 report. The company's operating expenses are lower now in the absence of Checkpoint, the analyst tells investors in a research note.
